Jazz Pharmaceuticals ( NASDAQ:JAZZ – Get Free Report ) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the company earned $5.30 earnings per share. The business's quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.